Steroid hormone receptor prefers working alone to shut off immune system genes

Researchers at Emory University School of Medicine have obtained a detailed molecular picture that shows how glucocorticoid hormones shut off key immune system genes.

The finding could help guide drug discovery efforts aimed at finding new anti-inflammatory drugs with fewer side effects.

The results are published in the journal Nature Structural & Molecular Biology.

Synthetic glucocorticoid hormones – for example, prednisone and dexamethasone—are widely used to treat conditions such as allergies, asthma, autoimmune diseases and cancer. They mimic the action of the natural hormone cortisol, which is involved in the response to stress and in regulating metabolism and the immune system. For this reason, synthetic glucocorticoids have a variety of severe side effects such as increased blood sugar and reduced bone density.

Both cortisol and synthetic hormones act by binding the glucocorticoid receptor, a protein that binds DNA and turns some on and others off. The hormone is required for the glucocorticoid receptor (GR) to enter the nucleus, giving it access to DNA.

For GR-targeting therapeutics, the desired anti-inflammatory effects are thought to come mainly from turning off inflammatory and immune system genes, while the side effects result from turning on genes involved in processes such as metabolism and bone growth.

The mechanism driving GR anti-inflammatory action has been debated, since was no GR binding site identified near these anti-inflammatory genes. Thus, GRs immunosupression was thought to occur indirectly, whereby GR blocks the ability of other critical DNA-binding proteins to stimulate gene expression. Last year French scientists discovered that the GR turns some genes off directly by recognizing a distinct DNA sequence used only in gene repression.

Eric Ortlund, PhD, Emory assistant professor of biochemistry, and first author William Hudson, a Molecular and Systems Pharmacology graduate student, used X-rays to probe crystals of GR bound to a stretch of DNA where it acts "repressively" to shut down the transcription of immune genes.

When the GR turns genes on, two GR molecules grasp each other while binding to DNA. However, the mode of binding to DNA at repressive sequences had remained unknown. Their analysis demonstrated that GR binds to repressive sites in pairs, but with two monomeric GR molecules located on opposite sides of the DNA helix.

"This unexpected geometry was still a surprise because GR has never been crystallized as a monomer bound to DNA, though previous studies proposed that GR monomers repress genes as opposed to GR dimers, which activate genes," says Ortlund.

In addition, the two GR molecules bind to different DNA sequences within the repressive DNA element, Hudson and Ortlund found. They also analyzed how mutations affected the ability of GR to bind repressive sites, showing that binding of the first GR molecule inhibits the binding of a second GR molecule. This "negative cooperativity" may play a role in ensuring that only GR monomers bind to DNA.

The study suggests that a drug preventing GR from interacting with other GR molecules while still allowing them to bind DNA and turn genes off may have anti-inflammatory effects with fewer side effects. One such plant-based compound, "compound A," has been under investigation by several laboratories.

"Our structural data could help scientists design synthetic hormones that separate these two aspects of GR function, potentially leading to improved steroid hormones for diseases ranging from asthma to autoimmune disorders," says Ortlund.

Related Stories

Controlling inflammatory and immune responses

Jul 12, 2012

Researchers at the IRCM, led by geneticist Dr. Jacques Drouin, recently defined the interaction between two essential proteins that control inflammation. This important breakthrough will be published in tomorrow's print edition ...

New target for developing effective anti-depressants

Apr 12, 2011

For the first time in a human model, scientists have discovered how anti-depressants make new brain cells. This means that researchers can now develop better and more efficient drugs to combat depression.

Platypus helps shed new light on mammalian evolution

Oct 20, 2011

(PhysOrg.com) -- A large international study published today in Nature has revealed new insights into how the regulation of the entire genome has changed during mammalian evolution over the past 200 millio ...

Recommended for you

Infant cooing, babbling linked to hearing ability

3 hours ago

Infants' vocalizations throughout the first year follow a set of predictable steps from crying and cooing to forming syllables and first words. However, previous research had not addressed how the amount ...

Developing 'tissue chip' to screen neurological toxins

4 hours ago

A multidisciplinary team at the University of Wisconsin-Madison and the Morgridge Institute for Research is creating a faster, more affordable way to screen for neural toxins, helping flag chemicals that ...

Gene mutation discovered in blood disorder

8 hours ago

An international team of scientists has identified a gene mutation that causes aplastic anemia, a serious blood disorder in which the bone marrow fails to produce normal amounts of blood cells. Studying a family in which ...

Airway muscle-on-a-chip mimics asthma

10 hours ago

The majority of drugs used to treat asthma today are the same ones that were used 50 years ago. New drugs are urgently needed to treat this chronic respiratory disease, which causes nearly 25 million people ...

User comments